EP1635732A1 - Stent pourvu d'un systeme de revetement - Google Patents

Stent pourvu d'un systeme de revetement

Info

Publication number
EP1635732A1
EP1635732A1 EP04739861A EP04739861A EP1635732A1 EP 1635732 A1 EP1635732 A1 EP 1635732A1 EP 04739861 A EP04739861 A EP 04739861A EP 04739861 A EP04739861 A EP 04739861A EP 1635732 A1 EP1635732 A1 EP 1635732A1
Authority
EP
European Patent Office
Prior art keywords
stent
substance
carrier
coating system
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04739861A
Other languages
German (de)
English (en)
Inventor
Claus Harder
Stéphane Delaloye
Bernd Heublein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotronik SE and Co KG
Original Assignee
Biotronik SE and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotronik SE and Co KG filed Critical Biotronik SE and Co KG
Priority to EP09170163A priority Critical patent/EP2138130A1/fr
Publication of EP1635732A1 publication Critical patent/EP1635732A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0035—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in release or diffusion time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Definitions

  • the invention relates to stents with coating systems composed of one or more polymeric carriers and at least one pharmacologically active substance, the substance being released into the surrounding tissue after implantation of the stent in the human or animal body.
  • Coronary artery disease especially acute myocardial infarction, is one of the most common causes of death in Western Europe and North America.
  • the cause of myocardial infarction is the thrombotic occlusion of a coronary artery due to rupture of atheromatous PIaque with pre-existing stenosing atheromatosis.
  • Decisive factors for the long-term prognosis after acute myocardial infarction are:
  • Non-surgical stenosis treatment methods have been established for more than twenty years, which include the narrowed or closed blood vessel is expanded again by balloon dilatation (PTCA percutaneous transluminal coronary angioplasty). This procedure has proven itself particularly in the treatment of acute myocardial infarction. With the widening of the blood vessel, however, the smallest injuries, tears, and dissections occur in the wall of the vessel, which often heal without problems, but in about a third of the cases lead to proliferation due to the triggered cell growth (proliferation), which ultimately leads to renewed growth Cause vasoconstriction (restenosis). The widening does not remove the causes of the stenosis, i.e. the physiological changes in the vascular wall.
  • Another cause of restenosis is the elasticity of the stretched blood vessel. After removing the balloon, the blood vessel contracts excessively, so that the cross-section of the vessel is reduced (obstruction, so-called negative remodeling). The latter effect can only be avoided by placing a stent.
  • restenosis occurs as a reaction of the vascular wall to the local injury due to stretching of the atherosclerotic PIaque.
  • the lumen-oriented migration and proliferation of the smooth muscle cells of the media and adventitia is induced by complex mechanisms of action (neointimal hyperplasia).
  • the smooth muscle cells produce a cover layer made of matrix proteins (elastin, collagen, proteoglycans), the uncontrolled growth of which can gradually lead to narrowing of the lumen.
  • Systemic drug therapy uses include oral administration of calcium antagonists, ACE inhibitors, anticoagulants, antiaggregants, fish oils, antiproliferative substances, anti-inflammatory substances and serotonin antagonists before, but significant reductions in the types of restenosis have not been achieved in this way to date.
  • the coating systems serve as carriers in which one or more pharmacologically active substances are embedded (local drug delivery, LDD).
  • LDD local drug delivery
  • the coating systems generally cover at least one peripheral wall of the endovascular implant facing the vessel wall.
  • Numerous preparations have hitherto been proposed as active ingredients or combinations of active ingredients for LDD systems.
  • the support of such coating systems consists of a biocompatible material, which is either of natural origin or can be obtained by synthetic means. Biodegradable coating materials offer particularly good tolerability and the possibility of influencing the elution characteristics of the embedded drug.
  • biodegradable polymers examples include cellulose, collagen, albumin, casein, polysaccharides (PSAC), polylactide (PLA), poly-L-lactide (PLLA), polyglycol (PGA), poly-D, L-lactide-co-glycolide (PDLLA / PGA), polyhydroxybutyric acid (PHB), polyhydroxyvaleric acid (PHV), polyalkyl carbonates, polyorthoesters, polyethylene terephthalate (PET), polymalonic acid (PML), polyanhydrides, polyphosphazenes, polyamino acids and their copolymers as well as hyaluronic acid and its derivatives.
  • PSAC polysaccharides
  • PLA polylactide
  • PLA poly-L-lactide
  • PGA polyglycol
  • PLLA / PGA polyhydroxybutyric acid
  • PHT polyhydroxyvaleric acid
  • PML polymalonic acid
  • polyanhydrides polyphosphazenes
  • the coating system covers the peripheral wall of the stent facing the vessel wall, at least in some areas.
  • the pharmacologically active substances are released in the human or animal body by gradual degradation of the carrier and / or diffusion into the surrounding tissue.
  • the elution characteristics of the substances can be estimated in advance using established in vitro tests.
  • LDD stents do not show any locally differentiated elution characteristics for the substances.
  • the coating systems in the area of the open end faces of the tubular base body of the stent and also in central areas of the stent are of approximately the same nature.
  • such coating systems can be disadvantageous, particularly in the case of elongated stenoses in which the lesion character changes over the length of the stent. This can be the case, for example, in the case of an elongated lesion to be treated with a specific substance, the amount of plaque in the center of which is very high and decreases towards the outside.
  • the marginal areas of the Stents overdosed, which can lead to a proliferation stimulus in these areas, while the same dosage in the central area of the lesion has an anti-proliferative effect.
  • the discharge of the substances of an LDD stent is increased at its ends, ie in the area of its open end faces, which can lead to local underdosing.
  • the task is to create a coating system with which an optimal local active substance application over the entire length of the stent is possible.
  • the invention is based on a stent with a crude base body which is open on its end faces and whose peripheral wall is covered at least in regions with a coating system composed of one or more polymeric carriers and at least one pharmacologically active substance.
  • the stent according to the invention is characterized in that one or more parameters of the coating system, namely
  • Coating system in the sense of the invention means the combination of a polymeric, optionally biodegradable carrier with at least one pharmacologically active substance.
  • the coating system covers an outer surface of the stent at least in regions.
  • “Pharmacologically active substance” is understood to mean a medicament that is used in a suitable dosage as a therapeutic agent for influencing conditions or functions of the body, as a substitute for natural active substances produced by the human or animal body and for eliminating or rendering harmless pathogens or foreign substances ,
  • “Local elution characteristic” is understood to mean the release of a substance into the neighboring tissue environment over a certain period of time, namely spatially limited to a predetermined partial area of the coated stent.
  • the concentration of the substance is increased in a central section of the stent, the local dosage in this section is also increased. If a local lesion extends in this section of the stent, it can be treated in a highly potent manner with optimal dosage. In contrast, the dosage of the substance decreases in the direction of the end face, so that proliferation stimuli are avoided.
  • neointima formation tends to be increased at the ends of the stent. It is therefore sensible to establish coating systems in these areas which have a substance which inhibits or suppresses the formation of neointima in a concentration which is higher than the central areas of the stent. This increases the dose of the substance in the vascular tissue opposite at the ends.
  • the local elution characteristic over the length of the stent can also be influenced by varying the layer thickness of the support. The focus here is on maintaining the dosage over a certain period of time. Depending on the pathophysiological conditions in the individual vascular sections opposite the circumferential wall of the stent, it is necessary to maintain drug treatment for a certain period of time. The dosing period can be extended with an increased layer thickness. Of course, depending on the application, the layer thickness, morphological structure, material modification and concentration of the substance can be varied.
  • “Morphological structures” in the sense of the invention mean the conformation and aggregation of the polymers forming the carrier. This includes the type of molecular order structure, the porosity, the surface properties and other intrinsic properties of the carrier, the diffusion of the active ingredient or the degradation behavior of the carrier Molecular order structures include amorphous, (partially) crystalline or mesomorphic polymer phases, which can be influenced or generated depending on the respective manufacturing process, coating process and environmental conditions. By targeted variation of the manufacturing and coating process, the porosity and The general rule is that the active substance is released more quickly with increasing porosity of the carrier. Amorphous structures show a similar effect to (partially) crystalline structures e.
  • “Material modification” here means the production of blends from polymers and the addition of fillers and additives (additives) for the purpose of influencing the elution characteristics.
  • the carrier is preferably formed from a biodegradable polymer, so that the substance after implantation of the stent in the human or animal body also by gradual degradation of the carrier in the surrounding tissue is released.
  • the degradation behavior of the carrier thus represents a further variable with which the active substance release can be controlled, ie with which a differentiation of the elution characteristics in the sense of the invention is possible. Rapid degradation of the carrier leads to rapid release of the substance.
  • the rate of degradation of the biodegradable polymer is not only dependent on the polymer carrier material present in each case, but can also be influenced by varying the morphological structure and by material modification.
  • the local elution characteristic of the substance is determined in the axial direction, i.e. over the length of the stent, depending on the pathophysiological and / or rheological conditions to be expected in the application.
  • the pathophysiological aspects take into account the fact that the stent is usually placed in the vessel in such a way that it lies in the center of the lesion, i.e. H. the adjacent tissue at the ends and in the middle area of the stent is of different composition.
  • Rheological aspects in turn take into account the fact that the flow conditions, in particular in the area of the ends and in middle sections of the stent, are different. This can result in increased discharge of the substance at the ends of the stent due to stronger flow.
  • Rheological parameters can vary widely, particularly by specifying the stent design, and must be determined in individual cases. By taking the two parameters mentioned into consideration, an optimal dosage for the LDD therapy can be ensured over the entire dimension of the stent.
  • the release behavior of various polymeric carriers is preferably also included.
  • the degradation behavior of the carrier or carriers can also be influenced in the manner already described in order to vary the local elution characteristics.
  • one compared to the other existing carriers of rapidly degradable carriers can be provided in a specific area of the stent.
  • the faster degradation of the carrier in this area leads to a local increase in the dosage of the substance present in the same concentration in the other carriers as well.
  • Such a system is useful, for example, if an increase in the concentration of the substance in the carrier material leads to undesired crystallization processes, which in turn negatively influence the release behavior and long-term stability.
  • the coating system according to the invention can be represented using conventional coating techniques. Common masking techniques can be used for local application.
  • FIG. 1 shows a stent with a tubular base body which is open at its end faces and whose peripheral wall is covered with a coating system
  • FIGS. 2a, 2b show a schematic cross section along a longitudinal axis of a stent to illustrate the coating system according to the invention according to a first variant
  • 3a, 3b show a schematic cross section along a longitudinal axis of a stent to illustrate the coating system according to the invention according to a second variant
  • FIG. 4 shows a schematic cross section along a longitudinal axis of a stent to illustrate the coating system according to the invention according to a third variant
  • 5 shows a schematic cross section along a longitudinal axis of a stent to illustrate the coating system according to the fourth variant.
  • FIG. 1 shows a highly schematic perspective side view of a stent 10 with a tubular base body 14 that is open at its ends 12.1, 12.2.
  • a circumferential wall 16 of the base body 14 that extends radially about a longitudinal axis L consists of segments arranged next to one another in the axial direction, which in turn are composed of a large number of support elements arranged in a specific pattern. The individual segments are connected to one another via connecting webs and, in summary, result in the base body 14.
  • FIG. 1 the illustration of a specific stent design was deliberately dispensed with, since this is not necessary for the purpose of representing the coating system according to the invention and, moreover, an individual vidual adaptation of the coating system to the given geometric factors and other parameters is necessary.
  • the stent 10 of FIG. 1 shows in a highly schematic manner a coating system 26 in which a plurality of sections 20.1, 20.2, 22.1, 22.2, 24 of the outer circumferential surface 18 of the peripheral wall 16 are provided with coatings which differ in their properties.
  • the differences in the coatings in the individual sections 20.1, 20.1, 20.2, 22.1, 22.2, 24 consist in the fact that the biodegradable Distinguish their carrier and pharmacologically active substance from individual individual sections of coatings in their local elution characteristics for the pharmacologically active substance.
  • the sections 20.1 and 20.2 at the ends 12.1, 12.2 of the stent 10 release the substance over time with a first dosage which is higher for this substance than in the stronger ones sections 22.1, 22.2 and 24 arranged in the middle.
  • the coating system thus has two or more sections with locally different elution characteristics for the substance.
  • a local elution characteristic of one or more substances present in the coating system essentially depends on five factors: a) a concentration of the substances in the or more supports, b) a layer thickness of the supports, c) a degradation behavior of the supports, d) one morphological structure of the carrier and e) a material modification of the carrier.
  • Point a) takes into account the basic principle that an increase in the active ingredient concentration also results in a higher dosage. However, this phenomenon does not necessarily have to be linear and both the dose and the duration of release are influenced by other factors.
  • the principle of drug release through diffusion has been supported both theoretically and practically by numerous examples, so that on the one hand theoretical predictions for in vivo release are possible and on the other hand in vitro experiments with high accuracy can simulate the processes actually taking place in the body ,
  • a variation in the layer thickness of the carrier (point b)) while the concentration of the embedded substance remains the same generally influences the dosing time.
  • other effects can also occur at the phase interfaces, which additionally affect the release of the substance and thus the dose of the substance in a certain time interval.
  • the local elution characteristics depend on the morphological structure and material modifications of the supports (points d) and e)).
  • the porosity of the carriers can differ, a higher porosity leading to accelerated degradation and increased diffusion.
  • material modification it can be provided, for example, to add additives to the carriers which delay the enzymatic degradation.
  • a local elution characteristic of the one or more substances can be set, for example, whether there are several carrier systems or the concentrations of the one or more substances change in individual sections of the stent or the layer thicknesses of the carriers are changed.
  • the individual sections of the stent coating system are adapted depending on the pathophysiological and theological conditions to be expected in the application.
  • the pathophysiological conditions here mean the tissue structure changed by disease in the stented vascular area.
  • the stent is placed so that the lesion, i.e. H.
  • the fibroatheromatous PIaque is usually in the middle of the stent.
  • the adjoining tissue structures diverge in the axial direction over the length of the stent, and thus a different treatment may also be indicated locally under certain circumstances.
  • the theological conditions are understood to mean the flow conditions as they occur in the individual longitudinal sections of the stent after implantation of the stent.
  • the ends of the stent are flowed around more strongly than the central regions of the stent. This can result in increased degradation of the carrier or diffusion of the substance in the end regions.
  • optimal dosages are sought at the site of action to support the healing process. However, this must also apply at the local level if the tissue structures in this local area require divergent treatment. A dosage that is too low cannot support the healing process and a dosage that is too high can even be a counterproductive starting point for inflammatory processes.
  • polymers from the group cellulose, collagen, albumin, casein, polysaccharides (PSAC), polylactide (PLA), poly-L-lactide (PLLA), polyglycol (PGA), poly-D, L-lactide-co-glycolide can be used for this purpose (PDLLA PGA), polyhydroxybutyric acid (PHB), polyhydroxyvaleric acid (PHV), polyalkylcarbonates, polyorthoesters, polyethylene terephthalate (PET), polymalonic acid (PML), polyanhydrides, polyphosphazenes, polyamino acids and their copolymers and hyaluronic acid.
  • the polymers can be applied in pure form, in derivatized form, in the form of blends or as
  • Calcium antagonists are suitable as pharmacologically active substances which are used in particular to treat the consequences of percutaneous coronary interventions and RXR agonists.
  • FIG. 2a shows a highly schematic and simplified sectional view of the circumferential wall 16 with its coating system 26 applied to the outer circumferential surface 18.
  • the coating system 26 consists of two end sections 28.1 and 28.2 and a middle section. cut 30.
  • the entire coating system 26 is formed by a biodegradable carrier applied in a uniform layer thickness and a pharmacologically active substance.
  • Sections 28.1, 28.2, 30 differ in that the pharmacologically active substance is introduced into the carrier in higher or lower concentrations.
  • the concentration of the substance in the end sections 28.1, 28.2 is increased compared to the middle section 30.
  • the transition from a low concentration to a higher concentration can also run continuously over the entire length of the stent.
  • the coating system 26 shown in FIG. 1 is particularly suitable for two case constellations.
  • a largely uniform dosage over the entire stent length can be guaranteed.
  • substances that inhibit neointima formation can be provided in increased concentration in the end regions.
  • FIG. 2b discloses a second variant of a coating system 26 comprising a carrier and a pharmacologically active substance.
  • Sections 28.1, 28.2 correspond to those in FIG. 2a.
  • the section 30, however, is significantly reduced in its layer thickness. The consequence of this is that the dosage of the pharmacologically active substance in the opposite tissue areas is reduced, ie in particular a dosage time is shortened.
  • Such a layer arrangement is useful, for example, if the pharmacologically active substance should only reach the area of the lesion over a short period of time and then there may be an undesirable influence on the healing process.
  • FIG. 3a shows a coating system 26, in which two different carriers with a different degradation behavior are applied in sections 28.1, 28.2, 30 of stent 10. The same applies to the variation of the system according to FIG. 3b. In both coating systems 26, only one substance is distributed in a homogeneous concentration over both carriers.
  • the sections 28.1, 28.2 are covered by a carrier with a delayed degradation behavior compared to the carrier which is used in the middle section 30. Accordingly, the local elution characteristic of the substance is influenced, i. H. usually delayed at the end. Such a design is always useful if the end-of-dose metering is to be maintained over a longer period of time or if the substance is to be discharged due to the rheological conditions.
  • 3b shows in sections 28.1 and 28.2 a multi-layer structure of the coating system 26 in the radial direction.
  • a first section 32 the carrier with the delayed degradation behavior is again applied, while a section 34 with the faster degradable carrier is located radially outward.
  • FIG. 4 shows a coating system 26 in which two different pharmacologically active substances are applied to a single carrier.
  • a concentration of the substances changes continuously in the axial direction over the length of the stent.
  • a concentration of a first substance is indicated via the course of darkness, that of a second substance via the course of brightness.
  • a concentration of the first substance at the ends 12.1, 12.2 of the stent is greatly increased, while its concentration in the middle region decreases sharply.
  • the second substance lies in the central regions of the coating system 26 in an increased concentration tion before and decreases towards the ends 12.1 and 12.2.
  • Such a system is suitable, for example, for using the first substance to carry out a locally differentiated medicinal treatment at the ends 12.1 and 12.2 of the stent and to essentially treat the lesion in the middle region of the stent with the second substance.
  • the coating system 26 of FIG. 4 has been further differentiated by integrating an additional middle section 36 from another carrier, which also contains a further substance, into the coating system 26.
  • the carrier of the subsection 36 shows a very rapid degradation behavior and accordingly releases the further substance embedded in it very quickly and with a high dosage.
  • the first and second substances are then released, as already described under FIG. 4.
  • FIGS. 2a, 2b, 3a, 3b, 4 and 5 represent only highly schematic exemplary embodiments of the coating system 26 according to the invention. They can be combined with one another in a variety of ways. For example, it is conceivable to design a complex coating system that consists of several carrier systems with different substances in individual sections. The primary goal is always to optimize the local dosage of the substances in the opposite tissue sections.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un stent comprenant un corps de base tubulaire ouvert sur ses faces, la paroi périphérique de ce corps étant recouverte au moins partiellement d'un système de revêtement comprenant un ou plusieurs supports polymères et au moins une substance pharmacologiquement active, laquelle est libérée, après implantation du stent dans le corps d'un être humain ou d'un animal, dans les tissus environnants. L'objectif de l'invention est de créer un système de revêtement permettant d'obtenir une application locale optimale de la substance active. A cet effet, un ou plusieurs paramètres du système de revêtement selon l'invention, à savoir une concentration de la substance, une structure morphologique du ou des supports, une modification physique du ou des supports et/ou une épaisseur de couche du ou des supports, sont prédéterminés dans le sens longitudinal du stent de telle sorte que la substance présente une caractéristique d'élution qui soit prédéterminée en fonction des conditions pathophysiologiques et/ou rhéologiques escomptées dans l'application et qui varie localement dans le sens longitudinal du stent.
EP04739861A 2003-06-23 2004-06-14 Stent pourvu d'un systeme de revetement Ceased EP1635732A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09170163A EP2138130A1 (fr) 2003-06-23 2004-06-14 Extenseur revêtu avec profil d'élution axialement varié

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10329260A DE10329260A1 (de) 2003-06-23 2003-06-23 Stent mit einem Beschichtungssystem
PCT/EP2004/006379 WO2005000164A1 (fr) 2003-06-23 2004-06-14 Stent pourvu d'un systeme de revetement

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP09170163A Division EP2138130A1 (fr) 2003-06-23 2004-06-14 Extenseur revêtu avec profil d'élution axialement varié

Publications (1)

Publication Number Publication Date
EP1635732A1 true EP1635732A1 (fr) 2006-03-22

Family

ID=33521171

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09170163A Withdrawn EP2138130A1 (fr) 2003-06-23 2004-06-14 Extenseur revêtu avec profil d'élution axialement varié
EP04739861A Ceased EP1635732A1 (fr) 2003-06-23 2004-06-14 Stent pourvu d'un systeme de revetement

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09170163A Withdrawn EP2138130A1 (fr) 2003-06-23 2004-06-14 Extenseur revêtu avec profil d'élution axialement varié

Country Status (6)

Country Link
US (1) US20060241742A1 (fr)
EP (2) EP2138130A1 (fr)
JP (1) JP2007506467A (fr)
CN (1) CN1812755A (fr)
DE (1) DE10329260A1 (fr)
WO (1) WO2005000164A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060271168A1 (en) * 2002-10-30 2006-11-30 Klaus Kleine Degradable medical device
US20050137677A1 (en) * 2003-12-17 2005-06-23 Rush Scott L. Endovascular graft with differentiable porosity along its length
JP5312018B2 (ja) 2005-04-05 2013-10-09 エリクシアー メディカル コーポレイション 分解性の移植可能な医療装置
US7935379B2 (en) * 2005-11-14 2011-05-03 Boston Scientific Scimed, Inc. Coated and imprinted medical devices and methods of making the same
US7879086B2 (en) * 2006-04-20 2011-02-01 Boston Scientific Scimed, Inc. Medical device having a coating comprising an adhesion promoter
US20080255657A1 (en) * 2007-04-09 2008-10-16 Boston Scientific Scimed, Inc. Stent with unconnected stent segments
DE102007034041A1 (de) * 2007-07-20 2009-01-22 Biotronik Vi Patent Ag Medikamentendepots für medizinische Implantate
DE102007034364A1 (de) * 2007-07-24 2009-01-29 Biotronik Vi Patent Ag Degradierbarer Metallstent mit wirkstoffhaltiger Beschichtung
DE102007034363A1 (de) * 2007-07-24 2009-01-29 Biotronik Vi Patent Ag Endoprothese
DE102007059755A1 (de) * 2007-12-10 2009-06-18 Biotronik Vi Patent Ag Implantate mit membrandiffusionskontrollierter Wirkstofffreisetzung
DE102008020415A1 (de) 2008-04-24 2009-10-29 Biotronik Vi Patent Ag Biodegradierbare metallische Stents mit Wachsschicht
DE102008021894A1 (de) 2008-05-02 2009-11-05 Biotronik Vi Patent Ag Implantat umfassend eine Oberfläche mit verringerter Thrombogenität
DE102008040143A1 (de) 2008-07-03 2010-01-07 Biotronik Vi Patent Ag Degradierbarer Magnesium-Stent oder Medizinprodukt mit Beschichtung umfassend Dipyridamol
DE102008040572A1 (de) 2008-07-21 2010-01-28 Biotronik Vi Patent Ag Implantat mit Beschichtung
DE102008040573A1 (de) 2008-07-21 2010-01-28 Biotronik Vi Patent Ag Aptamer beschichtetes Implantat, Herstellverfahren und Verwendungen
DE102008040640A1 (de) * 2008-07-23 2010-01-28 Biotronik Vi Patent Ag Endoprothese und Verfahren zur Herstellung derselben
DE102008044316A1 (de) 2008-12-03 2010-06-10 Biotronik Vi Patent Ag Wirkstoffbeschichtetes Medizinprodukt, Verfahren zu dessen Herstellung und dessen Verwendungen
EP2338537A2 (fr) * 2009-12-21 2011-06-29 Biotronik VI Patent AG Implant revêtu aptamère, procédé de fabrication et utilisations
WO2012040814A1 (fr) * 2010-09-27 2012-04-05 Research In Motion Limited Procédé et système pour l'enregistrement automatique d'un fichier
CN102579172A (zh) * 2012-02-15 2012-07-18 北京航空航天大学 一种药物涂层支架
US9504554B2 (en) 2013-01-16 2016-11-29 Biotronik Ag Microstructured absorbable implant

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464450A (en) * 1991-10-04 1995-11-07 Scimed Lifesystems Inc. Biodegradable drug delivery vascular stent
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
CA2179083A1 (fr) * 1995-08-01 1997-02-02 Michael S. Williams Extenseurs a structure polymerique et metallique pour l'administration de medicaments
DE19539449A1 (de) * 1995-10-24 1997-04-30 Biotronik Mess & Therapieg Verfahren zur Herstellung intraluminaler Stents aus bioresorbierbarem Polymermaterial
US5843172A (en) * 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
WO1998056312A1 (fr) * 1997-06-13 1998-12-17 Scimed Life Systems, Inc. Protheses endovasculaires avec plusieurs couches d'une composition polymere biodegradable
US5972027A (en) * 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
CA2326828C (fr) * 1998-05-05 2008-07-22 Scimed Life Systems, Inc. Extenseur possedant des extremites lisses
AU6526100A (en) * 1999-08-06 2001-03-05 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US8252044B1 (en) * 2000-11-17 2012-08-28 Advanced Bio Prosthestic Surfaces, Ltd. Device for in vivo delivery of bioactive agents and method of manufacture thereof
IL137860A0 (en) * 2000-08-15 2001-10-31 Baruch David Coronary membrane covered stent
AU2001286940A1 (en) * 2000-09-22 2002-04-02 Kensey Nash Corporation Drug delivering prostheses and methods of use
US6254632B1 (en) * 2000-09-28 2001-07-03 Advanced Cardiovascular Systems, Inc. Implantable medical device having protruding surface structures for drug delivery and cover attachment
WO2002026281A1 (fr) * 2000-09-29 2002-04-04 Cordis Corporation Dispositifs medicaux avec enrobages
AU2002249826A1 (en) * 2000-12-22 2002-07-30 Avantec Vascular Corporation Delivery of therapeutic capable agents
US7077859B2 (en) * 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20020147420A1 (en) * 2001-02-01 2002-10-10 Morris Roy A. Casting aid and methods of forming casts
US20020133224A1 (en) * 2001-03-13 2002-09-19 Clara Bajgar Drug eluting encapsulated stent
EP1277449B2 (fr) * 2001-07-20 2012-07-11 Sorin Biomedica Cardio S.R.L. Stent
US6827737B2 (en) 2001-09-25 2004-12-07 Scimed Life Systems, Inc. EPTFE covering for endovascular prostheses and method of manufacture
US20030088307A1 (en) * 2001-11-05 2003-05-08 Shulze John E. Potent coatings for stents
KR20050010827A (ko) * 2002-05-20 2005-01-28 오르버스 메디칼 테크놀로지즈 인코포레이티드 약물 용리 이식성 의료 장치
US7396539B1 (en) * 2002-06-21 2008-07-08 Advanced Cardiovascular Systems, Inc. Stent coatings with engineered drug release rate
EP1539043B1 (fr) 2002-09-20 2013-12-18 Innovational Holdings, LLC Dispositif medical extensible pourvu d'ouvertures pour l'administration d'agents benefiques multiples
ATE461673T1 (de) * 2002-11-07 2010-04-15 Abbott Lab Verfahren zum anbringen eines medikaments auf eine prothese mittels eines flüssigstrahls
US7169178B1 (en) * 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005000164A1 *

Also Published As

Publication number Publication date
WO2005000164A1 (fr) 2005-01-06
JP2007506467A (ja) 2007-03-22
CN1812755A (zh) 2006-08-02
EP2138130A1 (fr) 2009-12-30
DE10329260A1 (de) 2005-01-13
US20060241742A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
EP1635732A1 (fr) Stent pourvu d'un systeme de revetement
DE60032102T2 (de) Beschichtung für einen stent
EP1389471B1 (fr) Procédé de préparation d'un stent implantable ayant un revêtement de poly-L-lactide de poids moléculaire élevé
DE69935716T2 (de) Stent mit glatten enden
EP1389472B1 (fr) Implant endovasculaire avec un revêtement actif
EP1562565B1 (fr) Utilisation d'un ou de plusieurs elements du groupe rassemblant l'yttrium, le neodyme et le zirconium
DE60303705T2 (de) Beschichteter Stent für die Freisetzung aktiver Substanzen
WO2005065576A1 (fr) Commande de la degradation d'implants biodegradables au moyen d'un revetement
DE60029925T2 (de) Stent mit vorrübergehenden haltebändern
EP1603606B1 (fr) Implant endovasculaire presentant un revetement au moins partiellement actif en ratjadon et/ou en un derive de ratjadon
DE60111743T2 (de) Arzneimittelkombinationen zur restenose-prävention
DE60217505T2 (de) Vorrichtungen zur Abgabe von therapeutischen Mitteln mit variablem Freisetzungsprofil
DE102005010100A1 (de) Medizinisches Instrument mit einer medikamentenfreisetzenden Beschichtung
DE19754870A1 (de) Gefäßprothese
EP1891996A2 (fr) Amélioration de la stabilité de stents métalliques biodégradables, procédé et utilisations
EP1393766A1 (fr) Implant endovasculaire pour injecter un principe actif dans le media d'un vaisseau sanguin
DE60114406T2 (de) Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen
EP2070558A2 (fr) Implants dotés d'une membrane permettant la diffusion contrôlée d'agent actif
EP2967934A1 (fr) Endoprothèse biorésorbable
EP1475110A1 (fr) Stent pour la libération contrôlée de médicaments
EP2701757B1 (fr) Tuteur vasculaire implantable
DE10031199A1 (de) Implantierbare Vorrichtung mit einem Bestandteil aus Poly-Aminosäure
EP2465476B1 (fr) Stent et son procédé de fabrication
EP3032949B1 (fr) Agent contenant des microparticules, servant à nettoyer et à protéger des surfaces techniques
EP1711213A1 (fr) Implant permettant de liberer une substance active dans un recipient traverse par un fluide corporel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070326

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20091018